Is EGFR expression important in non-small cell lung cancer?

Lee, S. M.
February 2006
Thorax;Feb2006, Vol. 61 Issue 2, p98
Academic Journal
The article discusses a meta-analysis of 18 studies aimed at reviewing whether epidermal growth factor receptor (EGFR) overexpression in non-small cell lung cancer (NSCLC) has an impact on survival. Nakamura and colleagues concluded that EGFR protein overexpression using the immunohistochemistry method was not associated with a poorer prognosis. Another report suggests that EGFR mutations are not associated with poorer survival.


Related Articles

  • Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. Xi-Qing Li; Xing-Long Yang; Gong Zhang; Si-Pei Wu; Xu-Bing Deng; Sheng-Jun Xiao; Qiu-Zhen Liu; Kai-Tai Yao; Guang-Hui Xiao // Journal of Translational Medicine;2013, Vol. 11 Issue 1, p1 

    Background: Although the prognostic roles of β-catenin expression in non-small cell lung cancer (NSCLC) have been reported in several immunohistochemical (IHC) studies, the results were not consistent because some studies lack sufficient number of the positive cases or did not evaluate the...

  • Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. Liang, Wenhua; Wu, Xuan; Fang, Wenfeng; Zhao, Yuanyuan; Yang, Yunpeng; Hu, Zhihuang; Xue, Cong; Zhang, Jing; Zhang, Jianwei; Ma, Yuxiang; Zhou, Ting; Yan, Yue; Hou, Xue; Qin, Tao; Dinglin, Xiaoxiao; Tian, Ying; Huang, Peiyu; Huang, Yan; Zhao, Hongyun; Zhang, Li // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, no head to head trials between these TKIs...

  • The role of erlotinib in advanced NSCLC. Goldsack, N. // Thorax;Nov2005, Vol. 60 Issue 11, p931 

    The article focuses on the role of erlotinib in advanced non-small cell lung cancer (NSCLC). Relapsed advanced NSCLC carries a dismal prognosis and new treatments are particularly welcome. The article examines the use of erlotinib, a tyrosine kinase inhibitor of the epidermal growth factor...

  • Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Tartarone, Alfredo; Lerose, Rose; Gallucci, Giuseppina; Ardito, Raffaele; Aieta, Michele // Medical Oncology;Sep2012, Vol. 29 Issue 3, p1599 

    Treatment for patients with advanced NSCLC generally consists of chemotherapy, but response rates are modest and recurrence occurs for most patients after standard first-line platinum-based doublet therapy. Tailoring therapy to individual patient according to certain prognostic and predictive...

  • Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Schmid, K; Bago-Horvath, Z; Berger, W; Haitel, A; Cejka, D; Werzowa, J; Filipits, M; Herberger, B; Hayden, H; Sieghart, W // British Journal of Cancer;8/24/2010, Vol. 103 Issue 5, p622 

    Background:In this report we investigated the combination of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway inhibition as a possible new therapeutic strategy for small cell lung cancer (SCLC).Methods:EGFR, p-AKT, p-ERK, p-mTOR and p-p70s6K protein...

  • High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Kim, D.-W.; Min, H. S.; Lee, K.-H.; Kim, Y. J.; Oh, D.-Y.; Jeon, Y. K.; Lee, S.-H.; Im, S.-A.; Chung, D. H.; Kim, Y. T.; Kim, T.-Y.; Bang, Y.-J.; Sung, S. W.; Kim, J. H.; Heo, D. S. // British Journal of Cancer;3/18/2008, Vol. 98 Issue 6, p1118 

    The purpose of this study was to investigate the prognostic value of tumour-associated macrophages with a focus on micro-anatomical localisation and determine whether molecular changes of the epidermal growth factor receptor (EGFR) are related to macrophage infiltration in resected non-small...

  • Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Ruiz, M. I. Galleges; Floor, K.; Steinberg, S. M.; Grünberg, K.; Thunnissen, F. B. J. M.; Belien, J. A. M.; Meijer, G. A.; Peters, G. J.; Smit, E. F.; Rodriguez, J. A.; Giaccone, G. // British Journal of Cancer;1/13/2009, Vol. 100 Issue 1, p145 

    The purpose of this study is to evaluate the prognostic value of the combined assessment of multiple molecular markers related to the epidermal growth factor receptor (EGFR) pathway in resected non-small cell lung cancer (NSCLC) patients. Tumour specimens of 178 NSCLC patients were collected and...

  • BAP1 is a good prognostic factor in advanced non-small cell lung cancer. Li-hong Fan; Li-na Tang; Lu Yue; Yi Yang; Zhong-li Gao; Zan Shen // Clinical & Investigative Medicine;2012, Vol. 35 Issue 4, pE182 

    Purpose: Non-small cell lung cancer (NSCLC) is the leading worldwide source of cancerrelated deaths. Although some drugs targeting epidermal growth factor receptor (EGFR) mutations have been developed, most advanced NSCLC is still incurable and new targets for anticancer drugs are in demand....

  • Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. Akira Ono; Toshiaki Takahashi; Keita Mori; Hiroaki Akamatsu; Takehito Shukuya; Tetsuhiko Taira; Hirotsugu Kenmotsu; Tateaki Naito; Haruyasu Murakami; Takashi Nakajima; Masahiro Endo; Nobuyuki Yamamoto // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Serum CYFRA 21-1 is one of the most important serum markers in the diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma. However, it remains unknown whether pretreatment serum CYFRA 21-1 values (PCV) may also have prognostic implications in patients...


Read the Article


Sign out of this library

Other Topics